Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab

• Published in: Internal Medicine Vol. 60; no. 4; pp. 639 - 643
• Main Authors: Kataoka, Hiroshi, Kodama, Fumihiro, Tomita, Tomoko, Kondo, Makoto, Nagasaka, Atsushi, Nishikawa, Shuji, Mukai, Masaya
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 15.02.2021; Japan Science and Technology Agency
• Subjects: acute respiratory distress syndrome; Adrenal Cortex Hormones - therapeutic use; Aged, 80 and over; Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Autoimmune diseases; Case Report; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - immunology; Cytokine Release Syndrome; cytokine storm; Diabetes mellitus; Drug Therapy, Combination; Dyspnea - etiology; Humans; Internal medicine; Male; Off-Label Use; Pandemics; Public health; Respiratory Distress Syndrome - drug therapy; Respiratory Distress Syndrome - etiology; Respiratory Insufficiency - drug therapy; Risk factors; SARS-CoV-2; Sjogren's syndrome; Sjogren's Syndrome - complications; Sjögren's syndrome; Supplements; tocilizumab; COVID-19; acute respiratory distress syndrome; tocilizumab; cytokine storm; Sjögren's syndrome

The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's sy...